Beyond Drug Discovery: The Nanotechnology Molecular Optimization (NMO) Benchmark
Generative molecular design is shaped by simple proxy benchmarks for drug-like properties and models pretrained on large pharmaceutical datasets. This combination yields strong benchmark metrics but limits transferability to domains structurally distinct from drug discovery. To overcome this limitation and drive discovery toward real, scientifically grounded targets, we introduce the Nanotechnology Molecular Optimization (NMO) Benchmark, which bridges machine learning (ML) and quantum materials science. NMO acts simultaneously as a rigorous testbed for the ML community and a discovery engine f
Lineage graph
Paper → model → repo connections mined from source citations (Tier-1 exact match).
Why these links exist
Every edge carries a method, confidence, and the source snippet that justified it — so bad links are debuggable.
- LinkedLinked via unknownData-driven surrogates of rational design enable antimicrobial peptide optimization →
- LinkedLinked via unknownHow a Google DeepMind Spin-off Hunts Hidden Drug Targets →
- LinkedLinked via unknownFrom virtual experiments to biomedical insight with synthetic data →
- LinkedLinked via unknownA near-autonomous AI chemist improves a challenging reaction in medicinal chemistry →
- LinkedLinked via unknownEmpowering biomedical evidence exploration and synthesis with deep knowledge graph research →
- PossiblePossibly related (embedding) · 52%deepmodeling/DeePTB →
